No products in the cart.
Pre-made Abituzumab benchmark antibody ( Whole mAb, anti-ITGAV therapeutic antibody, Anti-CD51/MSK8/VNRA/VTNR Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-003
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Abituzumab biosimilar, Whole mAb, Anti-ITGAV Antibody: Anti-CD51/MSK8/VNRA/VTNR therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Abituzumab is a humanized IgG2 monoclonal antibody (mAb) targeted at CD51 (an integrin) currently in development by Merck KGaA Darmstadt, Germany in an attempt to prevent bone lesion metastases in castration-resistant prostate cancer.
| Products Name (INN Index) | Pre-Made Abituzumab biosimilar, Whole mAb, Anti-ITGAV Antibody: Anti-CD51/MSK8/VNRA/VTNR therapeutic antibody |
|---|---|
| INN Name | Abituzumab |
| Target | ITGAV |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG2 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2013 |
| Year Recommended | 2014 |
| Companies | Merck |
| Conditions Approved | NA |
| Conditions Active | Colorectal cancer,Systemic scleroderma |
| Conditions Discontinued | Ovarian cancer,Prostate cancer,Solid tumours |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | ITGAV |
| Package |
Previous slide
Next slide
